Company Listing
GenSight

GenSight is developing ophthalmic therapeutics using gene therapy. The company is focused on a gene replacement therapy for Leber’s hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa. GenSight's lead product is in clinical trials in LHON patients. The company went public in July 2016.

 

BACK
Location
Paris, France
CEO
Bernard Gilly
Abingworth Partner
Genghis Lloyd-Harris
Website Address

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Company Listing

GenSight is developing ophthalmic therapeutics using gene therapy. The company is focused on a gene replacement therapy for Leber’s hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa. GenSight's lead product is in clinical trials in LHON patients. The company went public in July 2016.

 

Location
Paris, France
CEO
Bernard Gilly
Abingworth Partner
Genghis Lloyd-Harris
Website Address
BACK
 
Copyright Abingworth 2017